Donate to raise funds in order to purchase Tomo & LINAC machines to Apeksha Cancer Hospital, Sri Lanka
Auckland
Each year, more than 20,000 new cases of cancer are diagnosed in Sri Lanka - 76 new registrations per day. Government hospitals are unable to accommodate such high numbers, resulting in average waiting times for treatment being roughly around 5 to 6 months. The lack of treatments and limited facilities, along with the substantial cost have taken all hopes of survival from these less fortunate cancer patients.
Losing my close relatives and friends to cancer, I've experienced the struggle that families fight to save their loved ones. At times you can feel helpless, especially when you don't have enough funds or the right treatment when needed.
I have always felt the urge to support other families going through similar experiences so when I heard about the 'Fight Cancer Team', who tremendously helps Apeksha Cancer Hospital in Sri Lanka (previously, Maharagama Cancer Hospital), I knew I had to help.
In 2016, they started their first project by buying a PET CT scanner. Completing that in 2018, they have now commenced their second project to buy Linear Accelerator and Tomotherapy machines to Apeksha Cancer Hospital, in which patients will receive all these high quality treatments for free.
With just these two machines, patients can receive their treatments more efficiently, under the best technological facilities and without any waiting time.
This second project will cost around 5.5 million USD (8 million NZD) but every dollar counts to save a life. Therefore, my personal target is to raise at least 10 000 NZD in support. This huge task cannot be done alone so please help me to support this worthy cause.
REMEMBER: ONE BILLION STARTS WITH ONE
All funds go towards the 'Fight Cancer Team Fund' to buy these two machines for Apeksha Cancer Hospital in Sri Lanka
Your message will be displayed on the page and emailed to the donor.
Your new message will also be emailed to the donor.
Saving a blank entry will delete the current comment.